Guardant Health, Delfi Diagnostics, and Singular Genomics reported leadership changes across oncology liquid biopsy and genomics platforms. Guardant said Craig Eagle, chief medical officer, will resign effective May 8 after previously serving in medical affairs roles at Genentech and Pfizer. Delfi Diagnostics named Charles Newton to its board; the CFO background includes Lyell Immunopharma and prior healthcare investment banking leadership. Singular Genomics appointed John Stark as CEO, with Stark coming from Resolve Biosciences and prior roles at Quantum-Si and Celsee, while current CEO Josh Stahl transitions to an independent director role. Together, the moves signal ongoing strategic realignment in diagnostics leadership as companies navigate reimbursement pressure, evidence generation demands, and competitive differentiation in molecular profiling.